{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T03:38:32Z","timestamp":1762659512330},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2016,9,7]],"date-time":"2016-09-07T00:00:00Z","timestamp":1473206400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,9,7]],"date-time":"2016-09-07T00:00:00Z","timestamp":1473206400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s40261-016-0446-3","type":"journal-article","created":{"date-parts":[[2016,9,7]],"date-time":"2016-09-07T15:52:22Z","timestamp":1473263542000},"page":"985-992","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["A Randomized, Double-blind, Active-Controlled, Multi-center Study of Ilaprazole in the Treatment of Reflux Esophagitis"],"prefix":"10.1007","volume":"36","clinical-trial-number":[{"clinical-trial-number":"nct01107938","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Yan","family":"Xue","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianghong","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liya","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanren","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haitang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jielai","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,9,7]]},"reference":[{"key":"446_CR1","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1136\/gut.2004.051821","volume":"54","author":"J Dent","year":"2005","unstructured":"Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2005;54:710\u20137.","journal-title":"Gut."},{"key":"446_CR2","doi-asserted-by":"publisher","first-page":"14","DOI":"10.5056\/jnm.2011.17.1.14","volume":"17","author":"HK Jung","year":"2011","unstructured":"Jung HK. Epidemiology of gastroesophageal reflux disease in Asia: a systematic review. J Neurogastroenterol Motil. 2011;17:14\u201327.","journal-title":"J Neurogastroenterol Motil."},{"key":"446_CR3","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/ajg.2012.444","volume":"108","author":"PO Katz","year":"2013","unstructured":"Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108:308\u201328.","journal-title":"Am J Gastroenterol."},{"key":"446_CR4","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s00535-009-0072-4","volume":"44","author":"KY Ho","year":"2009","unstructured":"Ho KY, Kuan A, Zano F, et al. Randomized, parallel, double-blinded comparison of the ulcer-healing effects of ilaprazole and omeprazole in the treatment of gastric and duodnal ulcers. J Gastroenterol. 2009;44:697\u2013707.","journal-title":"J Gastroenterol."},{"key":"446_CR5","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1097\/MCG.0b013e3181e88515","volume":"45","author":"L Wang","year":"2011","unstructured":"Wang L, Zhou L, Lin S, et al. A new PPI, ilaprazole compared with omeprazole in the treatment of duodenal ulcer: a randomized double-blind multicenter trial. J Clin Gastoenterol. 2011;45:322\u20139.","journal-title":"J Clin Gastoenterol."},{"key":"446_CR6","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1185\/03007995.2011.639353","volume":"28","author":"L Wang","year":"2012","unstructured":"Wang L, Zhou L, Hu H, et al. Ilaprazole for the treatment of duodenal ulcer: a randomized, double-blinded and controlled phase III trial. Curr Med Res Opin. 2012;28:101\u20139.","journal-title":"Curr Med Res Opin."},{"issue":"1","key":"446_CR7","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1053\/gast.1996.v111.pm8698230","volume":"111","author":"D Armstrong","year":"1996","unstructured":"Armstrong D, Bennett JR, Blum AL, et al. The endoscopic assessment of esophagitis: a progress report on observer assesment. Gastroenterology. 1996;111(1):85\u201392.","journal-title":"Gastroenterology."},{"key":"446_CR8","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1016\/S0140-6736(06)68932-0","volume":"367","author":"P Moayyedi","year":"2006","unstructured":"Moayyedi P, Talley NJ. Gastro-oesophageal reflux disease. Lancet. 2006;367:2086\u2013100.","journal-title":"Lancet."},{"key":"446_CR9","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1111\/j.1572-0241.2006.00630.x","volume":"101","author":"N Vakil","year":"2006","unstructured":"Vakil N, vanZenten SV, Kahrilas P, Global Consensus Group, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101:1900\u201320.","journal-title":"Am J Gastroenterol."},{"issue":"1\/2","key":"446_CR10","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.cca.2008.02.003","volume":"391","author":"Y Li","year":"2008","unstructured":"Li Y, Zhang W, Guo D. Pharmacokinetics of the new proton pump inhibitor ilaprazole in Chines healthy subjects in relation to CYP3A5 and CYP2C19 genotypes. Clin Chim Acta. 2008;391(1\/2):60\u20137.","journal-title":"Clin Chim Acta."},{"key":"446_CR11","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/j.1751-2980.2011.00557.x","volume":"13","author":"YQ Du","year":"2012","unstructured":"Du YQ, Guo WY, Zou DW, et al. Acid inhibition effect of ilprazlole on Helicobacter pylori-negative healthy volunteers: an open randomized cross-over study. J Dig Dis. 2012;13:113\u20139.","journal-title":"J Dig Dis."},{"key":"446_CR12","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1177\/0091270011408611","volume":"52","author":"H Cho","year":"2012","unstructured":"Cho H, Choi MK, Cho DY, et al. Effect of CYP2C19 genetic polymorphism on pharmacokinetics and pharmacodynamics of a new proton pump inhibitor, ilaprazole. J Clin Pharmacol. 2012;52:976\u201384.","journal-title":"J Clin Pharmacol."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-016-0446-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-016-0446-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-016-0446-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T17:40:20Z","timestamp":1628617220000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-016-0446-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,7]]},"references-count":12,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["446"],"URL":"https:\/\/doi.org\/10.1007\/s40261-016-0446-3","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,7]]},"assertion":[{"value":"7 September 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The study was sponsored by Livzon Pharmaceutical Group Inc., China.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The study was sponsored by Livzon Pharmaceutical Group Inc., China.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Xianghong Qin is an employee of Livzon Pharmaceutical Group Inc. Yan Xue, Liya Zhou, Sanren Lin, Ling Wang, Haitang Hu, and Jielai Xia declare no conflicts of interest that affect the results of the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Ethics Committee of the Health Center of Peking University.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All study participants provided written informed consent before being included in the study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}